ICAN BioCell iPS

The possibility of developing pluripotent stem cells (inducible Pluripotent Stem cells, iPSc) from adult cells, i.e. capable of differentiating into other types of adult cells, has revolutionized the study of the molecular mechanisms of human diseases. This approach is particularly suitable for diseases of genetic origin. In this case, the adult cells, in particular the blood cells, are taken from sick donors carrying genetic mutations.
The ICAN BioCell iPS platform specializes in the production and genetic modification of iPS cells called genome editing and their differentiation into highly differentiated cells such as cardiomyocytes, endothelial cells, adipocytes, hepatocytes and intestinal cells. Pseudo-tissues called organoids are generated in vitro to form beating heart muscle or intestinal crypts. To produce a cardiac organoid, the cardiomyocytes are included in a mixture of hydrogel and fibrin in the presence of endothelial and smooth muscle cells and fibroblasts. This cardiac organoid will allow the establishment of complex interactions between these cells and subsequently be able to study certain physiological parameters such as the action potential and the heart rate.
ICAN BioCell iPS also manages the generation of genetically modified iPS clones using the Crispr/CAS9 technology, which allows the insertion of corrective templates into the genome to remove a mutation and thus generate isogenic clones with the same genetic background as the control mutated clone.

• Maintenance of iPS lines
• Differentiation and characterization of iPS
• Training in the culture of iPS and their differentiation

• 3 type II microbiological safety stations.
• 2 Lynxx systems allowing passage and maintenance of iPS lines.
• 2 CO2 incubators dedicated to iPS culture
• 1 CO2 incubator dedicated to the differentiation of iPS into mature cells.
• 1 tri-gas incubator for reprogramming somatic cells (fibroblasts, PBMC) into iPS.
• A cell counter and microscope.